Table 1.
Baseline characteristics of studies included.
| Study | Design | Stage | Number of participants | Number of nCT (%) | Median age (range),years old | Female / Male | Chemotherapy regimen | ||
|---|---|---|---|---|---|---|---|---|---|
| nCT | pCT | nCT | pCT | ||||||
| Foxtrot, UK,2012 |
RCT, Multi-center |
T3 with extramural depth ≥5 mm or T4 | 150 | 99 (66%) | 64 (31-82) | 65 (38-78) | 34/65 | 19/32 | OxMdG |
| Dehal, USA,2018 |
Retrospective, Multi-center |
T3 or T4 | 27575 | 921 (33%) | 58.4 (12.1)* | 61.5 (12.8)* | 388/533 | 13384/13270 | NA |
| Morton, UK,2019 |
RCT, Multi-center |
T3 with extramural depth ≥5 mm or T4 | 1053 | 699 (66%) | NA | NA | OxMdG | ||
| Gooyer, NLD,2020 |
Retrospective, Multi-center |
T4 | 2146 | 192 (9%) | 64 (29-84) | 64 (25-88) | 91/101 | 961/993 | NA |
| Karoui, France,2020 |
RCT, Multi-center |
T3 with extramural depth ≥5 mm or T4 | 104 | 52 (50%) | 65 (46-79) | 62 (30-75) | 22/30 | 19/33 | simplified FOLFOX-4 |
| Karoui, France,2021 |
RCT, Multi-center |
T3 with extramural depth ≥5 mm or T4 | 104 | 52 (50%) | 65 (46-79) | 62 (30-75) | 22/30 | 19/33 | simplified FOLFOX-4 |
| Silva, USA,2021 |
Retrospective, Multi-center |
T3 or T4 | 7694 | 599 (8%) | 60 (12)* | 68 (13)* | 228/371 | 3533/3562 | NA |
| Laursen, Denmark,2022 |
Retrospective, Multi-center |
T3 with extramural depth ≥5 mm or T4 | 1310 | 179 (14%) | 67 (60-73)† | 73 (67-80)† | 80/99 | 586/545 | NA |
nCT, neoadjuvant chemotherapy; pCT, postoperative chemotherapy; RCT, randomized controlled trial; NA, not available.
*Presented with median (standard deviation).
†Presented with mean or mean (standard deviation).